Article
BioCryst bags $250M in a debt and royalty deal as the executive team preps a new drug launch for HA
Rating:
0.0
Views:
80
Likes:
1
Library:
1
Three days after landing an FDA OK for their HAE drug berotralstat, BioCryst $BCRX now has some cash to see how far they can go in commercializing the therapy as Orladeyo. The biotech reported Monday morning that they've inked a deal with Royalty Pharma that trades a chunk of their
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value